Six Peptides: Enthusiasm from Integrative Practitioners

Six Peptides: Enthusiasm from Integrative Practitioners by Jeffrey Dach MD October 30, 2026 is starting date for a more liberal policy regarding 6 peptides by Department of Health and Human Services (HHS) under Secretary Robert F. Kennedy Jr. Under this new policy, the FDA does not specifically approve the 6 peptides. However they will not take enforcement action against them. Specifically, this allows state-licensed 503A pharmacies to compound these six peptides for an individual patient with a valid prescription.(1) Header Image: Cover of "Peptide Handbook: A Professional's Guide to Peptide Therapeutics" by James B LaValle RPh Link to Book on Amazon. What the NEW Policy Actually Allows: The six peptides covered are: BPC-157 acetate (subcutaneous, intramuscular, oral, or topical), TB-500 acetate (subcutaneous or intramuscular), MOTS-c acetate (subcutaneous or intramuscular), Epitalon acetate (subcutaneous or intramuscular in intermittent or short courses), Semax free base (intranasal), and KPV acetate (oral or topical). Note: TB-500 typically refers to a short fragment of the parent molecule thymosin β4. This is Not Full FDA Approval of the 6 Peptides. The policy is enforcement discretion only. It does not evaluate safety or efficacy and does not place these peptides on the 503A bulk drug substances list. It is interim and lasts only until FDA completes rulemaking on each peptide’s status. HHS can revise or withdraw the policy if safety or quality problems arise. Strict conditions apply: The prescription must be patient-specific. The product may contain only a single active ingredient with no blends or “stacks”. The bulk substance must come from an FDA-registered manufacturer with a proper certificate of analysis. Adverse events and quality issues must be reported to FDA via MedWatch and to state authorities. Labeling requirements must be met. The pharmacy must comply with 503A standards. Only certain delivery devices (such as plain FDA-cleared syringes) may be used. “Research use only” products, foreign gray-market vials, and non-pharmacy sellers remain outside the policy. State pharmacy laws continue to apply. Comments on the policy are open for two weeks after the October 30 Federal Register publication. The Evidence Reality Check Because these are not patented products, there is no money for randomized clinical trials. As a result, none of these 6 peptides has established high-quality randomized clinical trial evidence for therapeutic use in humans. Most data comes from pre-clinical studies from animal, cell-culture, or small uncontrolled studies. Human trials are limited, low-certainty, or absent for several of them. BPC-157: Tissue Repair and Gut Healing BPC-157 is promoted primarily for tissue repair and musculoskeletal healing (tendons, ligaments, joints, and gut). Integrative practitioners are enthusiastic because of consistent animal data showing accelerated tendon, ligament, and gut healing, combined with a growing body of clinical anecdotes suggesting rapid recovery from soft-tissue injuries and gastrointestinal complaints with an apparently favorable short-term safety profile. Many view it as a tool that supports the body’s own repair mechanisms rather than merely suppressing symptoms. In 2021, Dr. Edwin Lee and Dr. Blake Padgett published a small retrospective chart review of intra-articular BPC-157 injections for multiple types of knee pain. Approximately sixteen patients were reviewed; most reported pain improvement, but there was no control group.(2) In 2003, Dr. Mario Staresinic and colleagues showed that daily intraperitoneal BPC-157 accelerated healing of surgically transected rat Achilles tendons, improving biomechanical strength, functional scores, histologic organization, and macroscopic appearance compared with saline.(3) In 2006, Dr. A. Krivic and colleagues reported that BPC-157 improved tendon-to-bone healing after Achilles detachment in rats and partially opposed the deleterious effects of methylprednisolone.(4) BPC-157 for Interstitial Cystitis In 2024, Dr. Edwin Lee and colleagues described an open-label pilot of twelve women with interstitial cystitis who received a single 10 mg intravesical injection of BPC-157; all reported substantial symptom resolution and no adverse events.(5) What Do Clinicians Say About BPC-157? Dr. Gary E. Foresman, MD, has written that in his clinical practice BPC-157 “has been amazing when it comes to wound healing and surgical recovery,” and that “as time has gone on, and my anecdotal experience grows, I have to admit that it is worth trying, due to its safety profile and well-documented mechanisms of action."(“BPC-157: What We Actually Know,” Middle Path Medicine / Substack, 2025; ). Orthopedic surgeon and sports medicine specialist Dr. David Geier has reviewed the preclinical literature and noted that animal studies of BPC-157 (including transected Achilles tendons and MCL ligament injuries) show improved biomechanical strength, function, and tissue organization compared with controls; he concludes that these findings “at least suggest that this peptide might help many tendon and ligament injuries in humans” such as ankle sprains, Achilles tendinitis, rotator cuff issues, and related soft-tissue problems, while emphasizing the need for rigorous human trials. (“BPC 157 for tendon and ligament injury healing,” Dr. David Geier, 2022; ). Internal medicine physician and peptide expert Dr. Abud Bakri has described both the animal data and personal experience. On the Huberman Lab podcast he recounted injecting BPC-157 locally after a grade-2 triceps tear (with visible bruising from shoulder to elbow); his physical therapist noted unexpectedly rapid healing, and he returned to activity in three to four weeks rather than the typical three-month recovery. He also highlighted animal studies in which BPC-157 accelerated healing after tendon and ligament severance and partially counteracted the negative effects of corticosteroids on wound repair. Huberman Lab episode and clips with Dr. Abud Bakri, “Peptides: The Science, Uses & Safety,” 2026; Functional medicine practitioner Dr. Matt Lewis has shared his own recovery from a chronic rotator cuff injury that had resisted conventional and alternative treatments for two years. Within two weeks of starting BPC-157 he estimated a 70 percent improvement in pain and function, regained the ability to sleep, hike, and play basketball and tennis, and subsequently began recommending the peptide to patients, the majority of whom reported similar results. (“Is There a Miracle Cure for Rotator Cuff and Other Joint Injuries?” and related BPC-157 articles, Provoke Health, 2023; ). These clinical observations align with the consistent animal data on accelerated soft-tissue repair but remain anecdotal or low-certainty; high-quality randomized controlled human trials are still lacking. The human reports remain small, uncontrolled, and of very low certainty. TB-500: Systemic Healing and the Wolverine Stack TB-500 (the short fragment of thymosin β4) is promoted for muscle and tendon repair and is frequently combined with BPC-157 in the so-called “Wolverine stack.” Practitioners are drawn to it because full-length thymosin β4 has demonstrated roles in cell migration, angiogenesis, and wound repair in preclinical models, and because clinical experience suggests additive benefits when paired with BPC-157 for stubborn musculoskeletal issues. The distinction between the fragment and the parent molecule is important and often under-appreciated. Human data exist primarily for the full-length parent molecule, not the fragment itself. In 2015, Dr. Gabriel Sosne and colleagues conducted a randomized, placebo-controlled phase II trial of thymosin β4 ophthalmic solution for dry eye using the Controlled Adverse Environment model; results were mixed and primary endpoints were not consistently met.(6) In 2010, Dr. David Ruff and colleagues reported that single and multiple intravenous doses of full-length thymosin β4 were well tolerated in healthy volunteers with no dose-limiting toxicity.(7) In 2021, Dr. Xinghe Wang and colleagues confirmed short-term intravenous safety and dose-proportional pharmacokinetics of recombinant human thymosin β4 in a first-in-human phase I study in healthy Chinese volunteers.(8) A small phase III trial of topical thymosin β4 for neurotrophic keratopathy showed a trend toward faster epithelial healing, but the sample size was only about eighteen patients.(9) What Do Clinicians Say? Dr. Henry Sobo, MD, has noted of the combination approach: “In my Stamford practice, we have used BPC-157 and Thymosin Beta-4 individually for years. The Wolverine Stack simply brings these two healing peptides together in a coordinated way, under medical supervision, to better support your body’s built-in repair mechanisms.” TB-500 Peptide Therapy page, Dr. Sobo Stamford; FDA has noted the absence of human exposure data specifically for the TB-500 fragment. Orthopedic surgeon and sports medicine specialist Dr. David Geier has reviewed the mechanisms of thymosin beta-4 (often discussed interchangeably with TB-500 in clinical settings), noting that it supports tissue stem cells, enhances collagen deposition, reactivates progenitor cells, promotes rapid wound healing with reduced scarring, and acts as a potent anti-inflammatory. He suggests it “might be very helpful for muscle injuries like hamstring, calf, and quadriceps injuries” or tendon problems such as tennis elbow, Achilles tendinopathy, and rotator cuff injuries, while acknowledging limited research specifically for musculoskeletal applications. Thymosin Beta 4 for orthopedic injuries,” Dr. David Geier, 2022. Sports medicine and orthopedic physician Dr. Jeffrey Peng, MD, has described limited personal clinical experience: “I have had a handful of patients try TB-500. Results have been mixed. Some reported faster recovery and reduced pain; others noticed no clear difference beyond standard rehabilitation.” He characterizes the peptide as “promising but unproven,” noting that “the biology makes sense and early safety data is encouraging, but we need large, well-designed human trials in orthopedic and sports medicine applications before confident recommendations.” TB-500 for Injury Recovery: What the Research Actually Shows,” Dr. Jeffrey Peng, MD, 2026; Board-certified internist Dr. David Nazarian has emphasized the evidence gaps while acknowledging the biological rationale. He notes that animal and laboratory studies suggest thymosin beta-4 can support cell migration, new blood-vessel growth, and wound repair, but “there are no published randomized trials showing that TB-500 injections speed recovery from muscle strains, tendon injuries or joint problems in people.” He reviews the evidence with patients and prioritizes treatments with stronger support. (TB-500 Peptide Therapy page, Dr. David Nazarian / My Concierge MD, 2026; https://www.myconciergemd.com/tb-500-peptide/). These perspectives reflect interest in the preclinical healing signals (cell migration, angiogenesis, reduced scarring) while consistently underscoring the lack of controlled human data for musculoskeletal recovery, particularly for the TB-500 fragment as distinct from full-length thymosin β4. MOTS-c: Mitochondrial and Metabolic Support MOTS-c is promoted for metabolic regulation, insulin sensitivity, obesity, and energy homeostasis. Interest in the integrative community stems from its origin as a mitochondrial-encoded peptide that rises with exercise, activates AMPK, and improves metabolic parameters in animal models—offering a potential “exercise mimetic” pathway for patients with insulin resistance or age-related metabolic decline. In 2015, Dr. Changhan Lee and colleagues published the key discovery paper showing that the mitochondrial-derived peptide MOTS-c prevents diet-induced obesity and insulin resistance in mice.(10) In 2021, Dr. Joseph C. Reynolds and colleagues demonstrated that exogenous MOTS-c enhances physical performance and healthspan in young, middle-aged, and old mice, while acute exercise in humans raises endogenous MOTS-c levels in skeletal muscle and plasma.(11) In 2021, Dr. Boyu Yang and colleagues reported synergistic effects of MOTS-c plus exercise on insulin resistance and glucose metabolism in high-fat-diet mice via AMPK signaling.(12) What Do clinicians Say? Dr. Amro Mahmoud has summarized the current state carefully: “MOTS-c is a legitimately interesting area of mitochondrial biology, and I understand why it has captured attention in the metabolic health and longevity space. The AMPK connection, the exercise mimetic properties, and the age related decline in circulating levels all make for a compelling research story. But a compelling mechanism in mice is not the same as a proven benefit in people. We do not have dosing data, long term safety data, or controlled human outcome trials for MOTS-c itself.” MOTS-c: A Physician’s Read,” Substack, 2026 Additional clinical voices highlight both the appeal of its metabolic and performance signals and the evidence gaps. Physician Dr. Craig Koniver has described MOTS-c as one of his favorites among mitochondrial peptides for fitness and body composition. He has characterized it as “the stronger, fitter, faster peptide: something that helped people with body composition and physical fitness, and helped them feel stronger and in better athletic shape.” Beyond physical changes, he noted interest in its effects on energy and motivation to train, observing that responses included improved athletic conditioning across various levels of athletes; he has expressed that he missed access to it after earlier regulatory restrictions. Koniver Wellness peptide research page; Discoverer Pinchas Cohen (USC) has publicly objected to unsupervised self-injection while supporting supervised, quality-controlled development. He stated, “Turns out that tens of thousands of people are injecting themselves with MOTS-c… I strongly object to that,” preferring regulated pathways and noting stalled efforts toward an approved analog. Quoted in Nootroholic review of Los Angeles Times reporting, August 18, 2026; Clinicians at practices such as AgeRejuvenation, under medical review by Dr. Dawn Ericsson, MD, describe MOTS-c as studied for supporting metabolic regulation, glucose handling, fatty acid use, and physical performance—particularly for patients with chronic fatigue of metabolic origin or early insulin resistance—while framing it within broader peptide protocols that require individualized assessment. AgeRejuvenation MOTS-c page, 2026; These perspectives reflect enthusiasm for the AMPK-linked, exercise-mimetic biology shown in animal models (improved insulin sensitivity, resistance to diet-induced obesity, and enhanced physical performance in aged mice) while consistently noting the absence of completed human interventional trials of exogenous MOTS-c itself. Epitalon: Telomeres, Circadian Rhythm, and Longevity Research Epitalon (also spelled Epithalon) is promoted for anti-aging, telomere lengthening, and circadian or neuroendocrine effects. Practitioners find the preclinical telomerase data and animal longevity signals intriguing, particularly the work originating from the St. Petersburg group, and some use short intermittent courses based on limited human biomarker reports involving melatonin and sleep. In 2003, Dr. V. Kh. Khavinson, Dr. I. E. Bondarev, and Dr. A. A. Butyugov reported that Epitalon induces telomerase activity and telomere elongation in human somatic cell cultures.(13) In 2003, Dr. Vladimir N. Anisimov and colleagues found that intermittent lifelong subcutaneous Epitalon in female SHR mice increased maximum lifespan and reduced leukemia incidence, although mean lifespan was unchanged.(14) In 2002, Dr. Vladimir N. Anisimov and colleagues showed that Epitalon prolonged lifespan and suppressed breast adenocarcinoma development in transgenic HER-2/neu mice.(15) Dr. Edwin Lee has described his clinical approach in conference materials: “I love epithalon… generally we do five milligrams subq daily for like 10 days… so like 10 days twice a year. It’s kind of a reset for your longevity… for me when I was doing it, it’s amazing, my sleep.” (Neuro-regenerative Peptides slides, as quoted in Peptide Dosing compilations; Human clinical data remain limited and low-quality; most published work originates from one research group. Epitalon: Telomeres, Circadian Rhythm, Melatonin and Sleep Epitalon (also spelled Epithalon) is promoted for anti-aging, telomere lengthening, and circadian or neuroendocrine effects.reclinical studies show Epitalon stimulates melatonin synthesis by the pineal and restores good quality sleep. Practitioners find the preclinical telomerase data and animal longevity signals intriguing, particularly the work originating from the St. Petersburg group, and some use short intermittent courses based on limited human biomarker reports involving melatonin and sleep. In 2003, Dr. V. Kh. Khavinson, Dr. I. E. Bondarev, and Dr. A. A. Butyugov reported that Epitalon induces telomerase activity and telomere elongation in human somatic cell cultures.(13) In 2003, Dr. Vladimir N. Anisimov and colleagues found that intermittent lifelong subcutaneous Epitalon in female SHR mice increased maximum lifespan and reduced leukemia incidence, although mean lifespan was unchanged.(14) In 2002, Dr. Vladimir N. Anisimov and colleagues showed that Epitalon prolonged lifespan and suppressed breast adenocarcinoma development in transgenic HER-2/neu mice.(15) What Do Clinicians Say? Dr. Edwin Lee has described his clinical approach in conference materials: “I love epithalon… generally we do five milligrams subq daily for like 10 days… so like 10 days twice a year. It’s kind of a reset for your longevity… for me when I was doing it, it’s amazing, my sleep.”Neuro-regenerative Peptides slides, as quoted in Peptide Dosing compilations; Restoration of Melatonin Synthesis, and Cortisol Dr. Sandeep Palakodeti, MD MPH, has written: “I’m pretty convinced, personally, on the power of Epitalon… Have run several cycles myself and increasingly have patients reporting same outcomes… I’ve seen others state it’s ‘not a sleep peptide’. That’s…not really true… strongest mechanism is restoration of melatonin synthesis and normalization of cortisol, both of which are major causes of sleep disruption. From his 2001 monkey study: ‘Epitalon was proven to significantly stimulate melatonin synthesis in senescent monkeys in the evening, thereby normalising the circadian rhythm of cortisol secretion.’” (X post, May 1, 2026; ). Dr. Shantanu Baghel, DO, board-certified in psychiatry, has noted the evidentiary limits while acknowledging the proposed mechanism: “The FDA’s reviewers searched for human studies of epitalon in insomnia and found none… The mechanism people cite, restoring an age-related decline in melatonin, rests on studies that measured melatonin metabolites rather than sleep.” He further observed that the July 2026 advisory committee vote addressed the insomnia indication. Epitalon Peptide and Sleep: What the Evidence Shows,” thebh.us, updated October 2026 At Formation in Tampa, medically reviewed content associated with Dr. Gopal Grandhige, MD, states that “Patients who use Epitalon under medical supervision… commonly report noticeable improvements in sleep onset, sleep depth, and morning alertness within the first one to two weeks of a treatment cycle.” The piece ties this to primate data showing stimulation of evening melatonin synthesis and cortisol rhythm normalization. Can Epitalon Help With Sleep?,” formationmed.com, May 2026 Brenda Halliday, NP, of Journey Health Institute, has summarized the practical appeal: “This is the area with the most human data, and the most practical payoff for most people. In older adults, pineal peptides including Epitalon helped restore the nighttime rise in melatonin that fades with age… Better melatonin timing is tied to deeper, more consistent sleep.” Epitalon: A Longevity Peptide for Sleep and Healthy Aging,” journeyhealthinstitute.com, October 22, 2026 ). Human clinical data remain limited and low-quality; most published work originates from one research group, and controlled trials measuring actual sleep outcomes (rather than melatonin biomarkers) have not been identified. Semax Increases BDNF: Neuroprotection and Cognitive Support Semax is promoted for neuroprotection, stroke recovery, and cognitive support; it is approved for certain uses in Russia. Integrative interest centers on Russian clinical reports linking it to elevated BDNF and faster functional recovery after stroke, along with animal data showing neurotrophic effects, leading some practitioners to explore it for brain fog, focus, or recovery after neurologic stress. In 2018, Dr. E. I. Gusev and colleagues reported an open study of 110 post-stroke patients in which Semax raised plasma BDNF levels and was associated with faster functional gains on the Barthel index; the study was not placebo-controlled or blinded.(16) In 1997, Dr. E. I. Gusev and colleagues compared 30 patients with acute hemispheric ischemic stroke given intranasal Semax plus standard care with 80 similar patients receiving standard care alone and described faster regression of neurologic deficits supported by EEG and evoked-potential data; allocation was not randomized.(17) What Do Clinicians Say? Dr. Craig Koniver has shared clinical observations from his practice: “Dr. Koniver likes Semax, and says so plainly: it seems to be energizing for the nervous system, and it helps people with focus, mental clarity, and just feeling locked in… Semax raises BDNF… and in his words it allows the nervous system to communicate more efficiently.” Koniver Wellness peptide research page; Independent Western replication is limited. Dr. Diane Mueller, ND, LAc, DAOM, notes that Semax is studied for its ability to raise brain-derived neurotrophic factor (BDNF), “a protein your brain needs for neuroprotection and to repair and grow new neural connections,” with its best-documented action on hippocampal BDNF and TrkB signaling relevant to memory and learning. She has described its use in contexts of brain fog and cognitive recovery that have not responded fully to conventional approaches. Semax Peptide: Benefits, BDNF, and Brain Fog Relief, MyLymeDoc, 2026 Fitness and longevity author Ben Greenfield has listed Semax among his personal favorites for cognitive support, stating that “for a nootropic-like brain boost, the peptide Semax is one of my favorites, as it can provide hours of focused cognitive performance without deleteriously affecting sleep or causing any type of anxiety or jitters." Quoted in Peptide Dosing compilation from Ben Greenfield Life, 2022 Endocrinologist Dr. Edwin Lee, MD, has discussed Semax in the context of neuroregenerative peptides, noting suggested nasal dosing (e.g., 750 mcg per spray in each nostril once daily for a total of 1,500 mcg) and referencing the higher doses used in stroke studies (up to 18 mg/day), while emphasizing nasal delivery for brain access. Conference slides referenced in Peptide Dosing review These perspectives reflect interest in Semax’s ability to elevate BDNF (supported by rodent hippocampal data and the 2018 Russian stroke study of 110 patients showing higher plasma BDNF and faster functional gains) and support nervous system communication, focus, and recovery, while acknowledging that most human data remain Russian-origin, open-label or limited in independent Western replication. KPV: Melanocortin and Anti-Inflammatory Effects KPV is promoted for anti-inflammatory effects, especially in gut and IBD models and on the skin. Practitioners are interested because it is a short fragment of alpha-MSH that retains anti-inflammatory activity while lacking pigmentary effects, with clear preclinical evidence of PepT1-mediated uptake and NF-κB inhibition in intestinal models—making it attractive for gut inflammation protocols. What is Alpha-MSH? Alpha-MSH (α-MSH) is a natural 13-amino-acid peptide hormone produced by the pituitary. α-MSH is also produced in many extrapituitary sites, including the hypothalamus (especially the arcuate nucleus), skin (keratinocytes and melanocytes), immune cells, and other tissues. MSH is melanocyte stimulating hormone. It is generated from the larger precursor protein pro-opiomelanocortin (POMC), the same precursor that gives rise to ACTH (adrenocorticotropic hormone). Alpha-MSH is best known for two main roles: Pigmentation: It stimulates melanocytes (via the melanocortin-1 receptor, MC1R) to produce melanin, darkening the skin. This is the classic “melanocyte-stimulating” function. Anti-inflammatory / immunomodulatory effects: It reduces production of pro-inflammatory cytokines (such as TNF-α, IL-1, and IL-6), inhibits the NF-κB signaling pathway (a master switch for inflammation), and has been shown in many cell and animal studies to calm inflammatory responses in various tissues. Reference: Wang, Wei, et al. "Melanocortin regulation of inflammation." Frontiers in endocrinology 10 (2019): 683. It also influences appetite, energy balance, and other processes through different melanocortin receptors (MC3R, MC4R, etc.). Relation to KPV KPV is the short tripeptide fragment consisting of the last three amino acids of alpha-MSH (residues 11–13: Lys-Pro-Val). Researchers studied it because this small C-terminal piece retains much of alpha-MSH’s anti-inflammatory activity while lacking the full hormone’s strong pigmentary effects and broader receptor interactions. In short: alpha-MSH is the parent endogenous hormone; KPV is a simplified fragment of it that researchers have focused on for targeted anti-inflammatory potential (especially in gut and skin models). In 2008, Dr. Guillaume Dalmasso and colleagues showed that the tripeptide KPV is taken up via the PepT1 transporter, inhibits NF-κB and MAP-kinase signaling in human intestinal and immune cells, and reduces chemically induced colitis in mice.(18) In 2008, Dr. Klaus Kannengiesser and colleagues confirmed anti-inflammatory effects of KPV in DSS and T-cell-transfer colitis models; the benefit persisted in mice lacking functional MC1R, suggesting partial receptor independence.(19) Dr. Craig Koniver has described practical experience: “For several years, KPV was a peptide we reached for often… Dr. Koniver used it most for gut inflammation, and after that for joint pain… ‘We had great success with it.’” He has also noted that “KPV and BPC-157 in particular seemed to complement each other. Koniver Wellness peptide research page” No published human clinical trials of KPV have been identified. Dr. Henry Sobo, MD, has explained the approach in his practice: “Our goal is to calm inflammation at its source rather than just masking symptoms… KPV peptide gives us a natural, cellular way to restore balance to the gut.” He has further noted that “KPV works from within the intestinal cells to calm the inflammatory cascade rather than suppressing the immune system,” and that “We often pair KPV and BPC-157 because one controls inflammation while the other repairs the tissue it affects.” He reports that “Patients often see improvement in gut comfort and fewer flare-ups when we integrate peptide-based anti-inflammatory therapy.KPV Peptide and Ulcerative Colitis, Dr. Sobo / Optimal Health Medical, 2025” Naturopathic physician and gastroenterology specialist Dr. Dan Wool, NMD, has described KPV as blocking the NF-κB pathway and reducing inflammatory cytokines such as TNF-α and IL-6. He highlights its potential for gut healing and barrier support, noting that in animal studies it helped reduce inflammation and speed healing in conditions like ulcerative colitis, while strengthening the intestinal lining to prevent leaky gut. He positions it as useful for IBD, ulcerative colitis, and related inflammatory presentations without systemic immune suppression KPV Peptide: An Anti-Inflammatory Ally for Gut, Skin, and Immune Health,” Dr. Dan Wool, 2025/updated 2026 . At Regen Health Physicians, Dr. Ajit Dhaliwal incorporates KPV into individualized protocols for chronic gut inflammation and autoimmune gastrointestinal conditions. The clinic materials describe its mechanisms as including inhibition of NF-κB activation (suppressing nuclear translocation and cytokine production), reduction of pro-inflammatory cytokines (IL-6, IL-8, TNF-α, IL-1β), and promotion of epithelial barrier repair through stimulation of intestinal epithelial cell migration and proliferation. KPV Peptide in NYC: A Targeted Approach to Inflammation and Gut Health,” Regen Health Physicians, 2026 These perspectives align with the preclinical data showing PepT1-mediated uptake, NF-κB/MAPK inhibition, and reduced inflammation in mouse colitis models, while the absence of published human trials remains the central limitation. Conclusion: For the above six peptides, let us review the mechanisms of repair, metabolic signaling, or anti-inflammation. For BPC-157, Dr. Gary E. Foresman, MD, has written that in his practice it “has been amazing when it comes to wound healing and surgical recovery,” adding that its safety profile and documented mechanisms make it “worth trying.” Dr. Henry Sobo, MD, has used both BPC-157 and thymosin β4 (the parent of TB-500) for years and views the “Wolverine Stack” as a coordinated way to support the body’s built-in repair mechanisms under medical supervision. Orthopedic voices such as Dr. David Geier have highlighted thymosin β4’s actions on progenitor cells, collagen deposition, and reduced scarring in soft-tissue injuries, while Dr. Jeffrey Peng, MD, has called TB-500 “promising but unproven” on the basis of mixed patient reports of faster recovery. For MOTS-c, Dr. Craig Koniver has described it as one of his favorite mitochondrial peptides—the “stronger, fitter, faster” agent that supported body composition and athletic conditioning—while discoverer Pinchas Cohen has acknowledged widespread use even as he objects to unsupervised self-injection and prefers regulated development. KPV has drawn similar practical comments: Dr. Koniver reported “great success” with it for gut inflammation and joint pain and noted its complementarity with BPC-157; Dr. Henry Sobo has used it to “calm inflammation at its source” rather than merely mask symptoms and has paired it with BPC-157 for gut repair; Dr. Dan Wool and clinics such as Regen Health Physicians emphasize its NF-κB inhibition, cytokine reduction, and support for epithelial barrier healing. Parallel interest exists for Epitalon (telomerase and cellular aging pathways) and Semax (neuroprotection, BDNF, and stroke-recovery signals), though these rest more heavily on older Russian literature and preclinical work. Here is a list of the six peptides and their proposed actions: BPC-157 — a gastric pentadecapeptide that in animal models promotes angiogenesis, fibroblast migration, and nitric-oxide modulation, supporting tendon, ligament, gut, and wound healing. TB-500 (thymosin β4 fragment) — an actin-binding peptide fragment that in preclinical models enhances cell migration, angiogenesis, and reduction of scar tissue in muscle, tendon, and soft-tissue injury. MOTS-c — a mitochondrial-encoded peptide that activates AMPK, improves insulin sensitivity, and acts as an exercise mimetic in rodent models of obesity, metabolic dysfunction, and age-related physical decline. Epitalon — a synthetic tetrapeptide studied primarily in animal and limited human work for telomerase induction, telomere elongation, and potential effects on cellular aging and pineal regulation. Semax — a synthetic ACTH(4-7) analog with documented effects (mainly Russian literature) on BDNF elevation, neuroprotection, and functional recovery after ischemic stroke. KPV — the C-terminal tripeptide of α-MSH that, via PepT1-mediated uptake, inhibits NF-κB and MAPK signaling and reduces colitis in mouse models of intestinal inflammation. These peptides are widely discussed in wellness and integrative contexts on the basis of largely preclinical work and clinical anecdote. The enthusiasm of experienced practitioners—centered on tissue repair, mitochondrial signaling, NF-κB inhibition, and neuroprotective pathways—is understandable given the biological plausibility and the gaps left by conventional therapies. High-quality randomized human evidence remains scarce or nonexistent for most of the promoted indications; human data, when present, are typically small, uncontrolled, open-label, or confined to related parent molecules or analogs. The new HHS enforcement-discretion policy creates a narrow, regulated pathway for patient-specific compounding under strict conditions (single-ingredient, COA-sourced, MedWatch reporting, etc.), but it does not constitute FDA approval, does not add the substances to the 503A bulk list, and does not establish efficacy or long-term safety. Peptides remain investigational substances. Any use should be undertaken only under the supervision of a knowledgeable physician who understands both the limited evidence and the specific requirements of the policy, who can monitor response and safety, and who can place these agents in the context of established care rather than as substitutes for it. Articles with related interest: NAC and Glycine Prevents Decline of Aging and Prolongs Lifespan Anti-Aging Breakthrough reset cellular clock with Demethylation Jeffrey Dach MD 7450 Griffin Road, Suite 190 Davie, FL 33314 www.jeffreydachmd.com References 1. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register notice scheduled for October 30, 2026 (FR Doc. 2026-22192). See also BakerHostetler analysis, October 2026. 2. Lee, Edwin, and Blake Padgett. “Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.” *Alternative Therapies in Health and Medicine*, vol. 27, no. 4, 2021, pp. 8–13. https://pubmed.ncbi.nlm.nih.gov/34324435/ 3. Staresinic, Mario, et al. “Gastric Pentadecapeptide BPC 157 Accelerates Healing of Transected Rat Achilles Tendon and in Vitro Stimulates Tendocytes Growth.” *Journal of Orthopaedic Research*, vol. 21, no. 6, 2003, pp. 976–83. https://pubmed.ncbi.nlm.nih.gov/12919881/ 4. Krivic, A., et al. “Achilles Detachment in Rat and Stable Gastric Pentadecapeptide BPC 157: Promoted Tendon-to-Bone Healing and Opposed Corticosteroid Aggravation.” *Journal of Orthopaedic Research*, vol. 24, no. 5, 2006, pp. 982–89. https://pubmed.ncbi.nlm.nih.gov/16583442/ 5. Lee, Edwin, et al. “Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.” *Alternative Therapies in Health and Medicine*, vol. 30, no. 10, 2024, pp. 12–17. https://pubmed.ncbi.nlm.nih.gov/39325560/ 6. Sosne, Gabriel, et al. “Thymosin Beta 4 Ophthalmic Solution for Dry Eye: A Randomized, Placebo-Controlled, Phase II Clinical Trial Conducted Using the Controlled Adverse Environment (CAE™) Model.” *Clinical Ophthalmology*, vol. 9, 2015, pp. 877–84. https://pubmed.ncbi.nlm.nih.gov/26056426/ 7. Ruff, David, et al. “A Randomized, Placebo-Controlled, Single and Multiple Dose Study of Intravenous Thymosin β4 in Healthy Volunteers.” *Annals of the New York Academy of Sciences*, vol. 1194, 2010, pp. 223–29. https://pubmed.ncbi.nlm.nih.gov/20536471/ 8. Wang, Xinghe, et al. “A First-in-Human, Randomized, Double-Blind, Single- and Multiple-Dose, Phase I Study of Recombinant Human Thymosin β4 in Healthy Chinese Volunteers.” *Journal of Cellular and Molecular Medicine*, vol. 25, no. 17, 2021, pp. 8222–28. https://pubmed.ncbi.nlm.nih.gov/34346165/ 9. Sosne, Gabriel, et al. (Phase III neurotrophic keratopathy data). “0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial.” *International Journal of Molecular Sciences*, 2023. https://pubmed.ncbi.nlm.nih.gov/36613994/ 10. Lee, Changhan, et al. “The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance.” *Cell Metabolism*, vol. 21, no. 3, 2015, pp. 443–54. https://pubmed.ncbi.nlm.nih.gov/25738459/ 11. Reynolds, Joseph C., et al. “MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis.” *Nature Communications*, vol. 12, article 470, 2021. https://pubmed.ncbi.nlm.nih.gov/33473109/ 12. Yang, Boyu, et al. “MOTS-c Interacts Synergistically with Exercise Intervention to Regulate PGC-1α Expression, Attenuate Insulin Resistance and Enhance Glucose Metabolism in Mice via AMPK Signaling Pathway.” *Biochimica et Biophysica Acta – Molecular Basis of Disease*, vol. 1867, no. 6, 2021, article 166126. https://pubmed.ncbi.nlm.nih.gov/33722744/ 13. Khavinson, V. Kh., I. E. Bondarev, and A. A. Butyugov. “Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells.” *Bulletin of Experimental Biology and Medicine*, vol. 135, no. 6, 2003, pp. 590–92. https://pubmed.ncbi.nlm.nih.gov/12937682/ 14. Anisimov, Vladimir N., et al. “Effect of Epitalon on Biomarkers of Aging, Life Span and Spontaneous Tumor Incidence in Female Swiss-Derived SHR Mice.” *Biogerontology*, vol. 4, no. 4, 2003, pp. 193–202. https://pubmed.ncbi.nlm.nih.gov/14501183/ 15. Anisimov, Vladimir N., et al. “Epithalon Decelerates Aging and Suppresses Development of Breast Adenocarcinomas in Transgenic HER-2/neu Mice.” *Bulletin of Experimental Biology and Medicine*, vol. 134, no. 2, 2002, pp. 187–90. https://pubmed.ncbi.nlm.nih.gov/12459848/ 16. Gusev, E. I., et al. “.” *Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova*, vol. 118, no. 3 Vyp. 2, 2018, pp. 61–68. https://pubmed.ncbi.nlm.nih.gov/29798983/ 17. Gusev, E. I., et al. “.” *Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova*, vol. 97, no. 6, 1997, pp. 26–34. https://pubmed.ncbi.nlm.nih.gov/11517472/ 18. Dalmasso, Guillaume, et al. “PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation.” *Gastroenterology*, vol. 134, no. 1, 2008, pp. 166–78. https://pubmed.ncbi.nlm.nih.gov/18061177/ 19. Kannengiesser, Klaus, et al. “Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel Disease.” *Inflammatory Bowel Diseases*, vol. 14, no. 3, 2008, pp. 324–31. https://pubmed.ncbi.nlm.nih.gov/18092346/

Jeffrey Dach MD

Bioidentical Hormones Natural Thyroid

Category Archives: Peptides

Six Peptides: Enthusiasm from Integrative Practitioners